Abstract
Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Central Nervous System Agents in Medicinal Chemistry
Title:The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary
Volume: 16 Issue: 3
Author(s): Da-Yong Lu, Peng-Peng Zhu, Ting-Ren Lu and Jin-Yu Che
Affiliation:
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Abstract: Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Export Options
About this article
Cite this article as:
Lu Da-Yong, Zhu Peng-Peng, Lu Ting-Ren and Che Jin-Yu, The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871524916666160210142734
DOI https://dx.doi.org/10.2174/1871524916666160210142734 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Evaluation of Response Surface Methodology to Predict Optimum Growth Conditions for Lactobacillus plantarum A7 (KC 355240) in Probiotic Soy Milk Containing Essential Oil of Cuminum cyminum
Recent Patents on Food, Nutrition & Agriculture Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Low Rank Representation and Its Application in Bioinformatics
Current Bioinformatics Editorial [Hot Topic: Current Drug Targets in Childhood Acute Leukemia (Guest Editor: R.B. Lock)]
Current Drug Targets Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Neurotrophins' Modulation by Olive Polyphenols
Current Medicinal Chemistry Gadolinium-Deferasirox-D-Glucosamine: Novel Anti-Tumor and MR Molecular (Theranostic) Imaging Agent
Current Radiopharmaceuticals The Double-Edged Nature of Recovery in First-Episode Psychosis
Current Psychiatry Reviews Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Vaccine Delivery - Current Trends and Future
Current Drug Delivery Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science